BioMed Research International / 2014 / Article / Tab 2

Research Article

The Clinicopathological Significance of MicroRNA-155 in Breast Cancer: A Meta-Analysis

Table 2

Analysis of miR-155 expression level and different subtype breast cancer.

Comparisons HeterogeneityModelaEffect size
Studies (%) ( )SMD ( )

ER+ Versus ER−7 [1618, 20, 22, 27, 29]96<0.00001R−1.20.03
PR+ Versus PR−7 [1618, 20, 22, 27, 29]97<0.00001R−1.850.01
Her2+ Versus Her2−4 [20, 22, 25, 29]500.11F0.320.007
LNM+ Versus LNM−7 [1518, 20, 22, 29]97<0.00001R2.620.0001
TNM I/II Versus III/IV8 [1518, 22, 26, 28, 29]96<0.00001R−0.940.08
TS 1 Versus 2/35 [16, 18, 20, 22, 29]92<0.00001R−0.58<0.0001
P53 WT Versus MT3 [16, 25, 28]650.06R−0.790.02

number of studies, ( ) value of test for heterogeneity, ( ) value of test for significant test, LNM lymph node metastasis, TS tumor size, WT wild type, MT mutant type.
aR: random-effect model; F: fixed-effect model.